# The Cancer Institute Hospital

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/the-cancer-institute-hospital/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 70 |
| Citations | 693,916 |
| City | Tokyo |
| Country | JP |
| Description | The Cancer Institute Hospital is a research organisation in Tokyo, JP. OpenAlex records 7,505 works and 693,916 citations for it. 1,208 researchers list it as their most recent affiliation. |
| Homepage | http://www.jfcr.or.jp/hospital-en/index.html |
| OpenAlex ID | https://openalex.org/I4210137039 |
| Researchers | 1,208 |
| ROR ID | https://ror.org/03md8p445 |
| Type | healthcare |
| Works | 7,505 |

## University papers

Showing 12 of 25.

- [First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer](https://scholariq.org/papers/first-line-atezolizumab-plus-chemotherapy-in-extensive-stage-small-cell-lung/)
- [Capmatinib in <i>MET</i> Exon 14–Mutated or <i>MET</i> -Amplified Non–Small-Cell Lung Cancer](https://scholariq.org/papers/capmatinib-in-i-met-i-exon-14-mutated-or-i-met-i-amplified-non-small-cell-lung/)
- [Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial](https://scholariq.org/papers/atezolizumab-plus-bevacizumab-and-chemotherapy-in-non-small-cell-lung-cancer/)
- [Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial](https://scholariq.org/papers/alectinib-versus-crizotinib-in-patients-with-alk-positive-non-small-cell-lung/)
- [The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non–Small Cell Lung Cancer](https://scholariq.org/papers/the-alk-inhibitor-ceritinib-overcomes-crizotinib-resistance-in-non-small-cell/)
- [Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)](https://scholariq.org/papers/updated-overall-survival-and-pd-l1-subgroup-analysis-of-patients-with-extensive/)
- [Adiponectin Stimulates AMP-Activated Protein Kinase in the Hypothalamus and Increases Food Intake](https://scholariq.org/papers/adiponectin-stimulates-amp-activated-protein-kinase-in-the-hypothalamus-and/)
- [Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer](https://scholariq.org/papers/efficacy-of-selpercatinib-in-i-ret-i-fusion-positive-non-small-cell-lung-cancer/)
- [Overview of the BioBank Japan Project: Study design and profile](https://scholariq.org/papers/overview-of-the-biobank-japan-project-study-design-and-profile/)
- [Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study](https://scholariq.org/papers/erlotinib-alone-or-with-bevacizumab-as-first-line-therapy-in-patients-with/)
- [Correlations between lymph node metastasis and depth of submucosal invasion in submucosal invasive colorectal carcinoma: a Japanese collaborative study](https://scholariq.org/papers/correlations-between-lymph-node-metastasis-and-depth-of-submucosal-invasion-in/)
- [Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study](https://scholariq.org/papers/osimertinib-for-pretreated-egfr-thr790met-positive-advanced-non-small-cell-lung/)

## University top topics

Showing 8 of 25.

- [Gastric Cancer Management and Outcomes](https://scholariq.org/topics/gastric-cancer-management-and-outcomes/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Esophageal Cancer Research and Treatment](https://scholariq.org/topics/esophageal-cancer-research-and-treatment/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Pancreatic and Hepatic Oncology Research](https://scholariq.org/topics/pancreatic-and-hepatic-oncology-research/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.